Based on the aforementioned reports, we conducted this cohort study to examine whether the predictive role of adiponectin in ESRD and all-cause mortality in non-diabetic patients with advanced CKD is independent of adiposity, especially BMI, and metabolic syndrome components. Here, ADIPOQ is linked to metabolic syndrome.